Early hydroxychloroquine and azithromycin as combined therapy for COVID-19: a case series

Siswanto Siswanto (Department of Pulmonology and Respiratory Medicine, Academic Hospital, Department of Physiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta)
Oktaviarum S. Utama (Department of Pulmonology and Respiratory Medicine, Academic Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta)
Agit S. Adisetiadi (Department of Internal Medicine, Academic Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta)
Maria E. Pranasakti (Department of Internal Medicine, Academic Hospital, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta)
Mohamad Saifudin Hakim (Department of Microbiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta)

Journal of the Medical Sciences (Berkala Ilmu Kedokteran)
Vol 52, No 3 (2020): Special Issue: COVID-19

Coronavirus disease 2019 (COVID-19) is a worldwide outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) has declared it as a public health emergency of international concern (PHEIC) and eventually a pandemic. Many clinical trials have been conducted to investigate potential and effective therapies for COVID-19. Here we reported the outcome of three COVID-19 cases treated early with the combination of hydroxychloroquine and azithromycin. Early treatments of suspected or confirmed positive COVID-19 cases with this combination therapy is to avoid disease progressions into a more severe and irreversible state. In these cases, clinical, radiological, and laboratory features were followed up. No complications were observed. The COVID-19 patients treated with this early combination therapy showed good clinical and virological responses.